AZ veteran Julie Brown becomes CFO at GSK
Plus AstriVax appoints chair and updates from Section 32, Janux and Alivamab
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Julie Brown to succeed Ian Mackay as CFO, effective May 1. Brown is chief operating and financial officer of Burberry Group plc; she held roles at AstraZeneca plc (LSE:AZN; NASDAQ:AZN) for 25 years before becoming CFO at Smith & Nephew plc (NYSE:SNN; LSE:SN), and was also on the board at Roche (SIX:ROG; OTCQX:RHHBY). The hire will put two women at the helm of GSK — the company has been led by CEO Emma Walmsley since 2017. BioCentury’s 2022 Back to School included a data analysis on women CEOs.
Jeanne Bolger will become chair at AstriVax N.V., a Belgium-based vaccine company. Bolger, who sits on multiple boards, was VP of venture investing at Johnson & Johnson Innovation – JJDC and held roles in scientific licensing at Johnson & Johnson (NYSE:JNJ) and GSK. The company raised a €30 million ($29.8 million) seed round in August, backed by V-Bio Ventures and Fund+...